Analysts Set Expectations for Immunocore FY2025 Earnings

Immunocore Holdings plc (NASDAQ:IMCR) – Equities researchers at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for Immunocore in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst E. Schmidt expects that the company will post earnings of ($2.33) per share for the year. The consensus estimate for Immunocore’s current full-year earnings is ($0.94) per share.

IMCR has been the subject of several other reports. Guggenheim lowered shares of Immunocore from a “buy” rating to a “neutral” rating in a research report on Monday, October 7th. Needham & Company LLC reiterated a “buy” rating and set a $71.00 price objective on shares of Immunocore in a research report on Friday, January 10th. Morgan Stanley restated an “equal weight” rating and issued a $35.00 target price (down previously from $74.00) on shares of Immunocore in a research report on Friday, December 13th. UBS Group began coverage on shares of Immunocore in a research report on Thursday, October 24th. They set a “sell” rating and a $24.00 price target on the stock. Finally, HC Wainwright restated a “buy” rating and issued a $100.00 price objective on shares of Immunocore in a report on Thursday, October 24th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $65.64.

Immunocore Trading Up 3.4 %

IMCR stock opened at $30.00 on Wednesday. The firm has a 50 day simple moving average of $30.56 and a two-hundred day simple moving average of $33.45. The company has a debt-to-equity ratio of 1.03, a current ratio of 3.78 and a quick ratio of 3.76. Immunocore has a one year low of $27.69 and a one year high of $76.98.

Immunocore (NASDAQ:IMCR) last issued its quarterly earnings data on Wednesday, November 6th. The company reported $0.17 EPS for the quarter, topping the consensus estimate of ($0.33) by $0.50. The company had revenue of $80.25 million during the quarter, compared to analyst estimates of $78.94 million. Immunocore had a negative return on equity of 12.84% and a negative net margin of 15.87%. Immunocore’s revenue was up 23.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.59) earnings per share.

Hedge Funds Weigh In On Immunocore

Several hedge funds and other institutional investors have recently modified their holdings of the company. Primecap Management Co. CA lifted its stake in Immunocore by 26.7% in the third quarter. Primecap Management Co. CA now owns 2,472,020 shares of the company’s stock worth $76,954,000 after acquiring an additional 520,950 shares during the period. State Street Corp lifted its position in shares of Immunocore by 63.9% in the 3rd quarter. State Street Corp now owns 76,671 shares of the company’s stock worth $2,387,000 after purchasing an additional 29,897 shares during the period. Frazier Life Sciences Management L.P. bought a new stake in shares of Immunocore during the 2nd quarter valued at about $3,686,000. Principal Financial Group Inc. increased its position in shares of Immunocore by 25.0% during the third quarter. Principal Financial Group Inc. now owns 546,318 shares of the company’s stock valued at $17,007,000 after buying an additional 109,206 shares during the period. Finally, Hennion & Walsh Asset Management Inc. raised its stake in Immunocore by 125.4% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 49,608 shares of the company’s stock worth $1,463,000 after buying an additional 27,598 shares in the last quarter. 84.50% of the stock is owned by institutional investors.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.